MA50582A - Méthodes de traitement et de protection contre une maladie cardiaque, une maladie cardiovasculaire et des états et des symptômes associés - Google Patents

Méthodes de traitement et de protection contre une maladie cardiaque, une maladie cardiovasculaire et des états et des symptômes associés

Info

Publication number
MA50582A
MA50582A MA050582A MA50582A MA50582A MA 50582 A MA50582 A MA 50582A MA 050582 A MA050582 A MA 050582A MA 50582 A MA50582 A MA 50582A MA 50582 A MA50582 A MA 50582A
Authority
MA
Morocco
Prior art keywords
symptoms
treatment
methods
protection against
associated conditions
Prior art date
Application number
MA050582A
Other languages
English (en)
Inventor
Jr Richard Thomas George
Chao-Yu Jin
Original Assignee
Alphacore Pharma Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alphacore Pharma Llc filed Critical Alphacore Pharma Llc
Publication of MA50582A publication Critical patent/MA50582A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1025—Acyltransferases (2.3)
    • C12N9/1029—Acyltransferases (2.3) transferring groups other than amino-acyl groups (2.3.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y203/00—Acyltransferases (2.3)
    • C12Y203/01—Acyltransferases (2.3) transferring groups other than amino-acyl groups (2.3.1)
    • C12Y203/01043—Phosphatidylcholine-sterol O-acyltransferase (2.3.1.43), i.e. lecithin-cholesterol acyltransferase or LCAT

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
MA050582A 2017-11-07 2018-11-05 Méthodes de traitement et de protection contre une maladie cardiaque, une maladie cardiovasculaire et des états et des symptômes associés MA50582A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762582382P 2017-11-07 2017-11-07
US201862629900P 2018-02-13 2018-02-13

Publications (1)

Publication Number Publication Date
MA50582A true MA50582A (fr) 2020-09-16

Family

ID=66438309

Family Applications (1)

Application Number Title Priority Date Filing Date
MA050582A MA50582A (fr) 2017-11-07 2018-11-05 Méthodes de traitement et de protection contre une maladie cardiaque, une maladie cardiovasculaire et des états et des symptômes associés

Country Status (12)

Country Link
US (1) US20200261549A1 (fr)
EP (1) EP3706781A4 (fr)
JP (1) JP2021501793A (fr)
KR (1) KR20200085292A (fr)
CN (1) CN111601614A (fr)
AU (1) AU2018362603A1 (fr)
CA (1) CA3082070A1 (fr)
IL (1) IL274360A (fr)
MA (1) MA50582A (fr)
SG (1) SG11202003835PA (fr)
TW (1) TW201929894A (fr)
WO (1) WO2019092584A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114999674B (zh) * 2022-05-27 2024-07-02 中国药科大学 Qsp-pbpk-td模型构建方法及药源性心功能损伤预测方法
US20240212139A1 (en) * 2022-12-22 2024-06-27 National Taiwan University Automatic calculation method of gray-to-white-matter ratio for head computed tomography of patients with cardiac arrest

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU728257B2 (en) * 1995-11-09 2001-01-04 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The The use of lecithin-cholesterol acyltransferase (LCAT) in the treatment of atherosclerosis
WO2006069371A1 (fr) * 2004-12-22 2006-06-29 Baylor College Of Medicine Methode de lipidation plasmatique destinee a prevenir, a inhiber et/ou a inverser l'atherosclerose
MY159075A (en) * 2007-07-26 2016-12-15 Amgen Inc Modified lecithin-cholesterol acyltransferase enzymes
EP2020603A1 (fr) * 2007-08-03 2009-02-04 BRAHMS Aktiengesellschaft Procédé de stratification du risque chez des patients ayant une maladie associeé avec des coronaropathies
ES2729051T3 (es) * 2009-07-29 2019-10-30 Kai Pharmaceuticals Inc Agentes terapéuticos para reducir los niveles de hormona paratiroidea
NZ603453A (en) * 2010-05-06 2014-12-24 Alphacore Pharma Llc Delivery of cholesteryl ester to steroidogenic tissues
US8999920B2 (en) * 2010-06-30 2015-04-07 Csl Limited Reconstituted high density lipoprotein formulation and production method thereof
CN104220460A (zh) * 2011-12-08 2014-12-17 安姆根有限公司 激动人lcat抗原结合蛋白和它们在疗法中的用途
IL312865B2 (en) * 2013-09-11 2025-06-01 Eagle Biologics Inc Liquid protein formulations containing viscosity-lowering agents
US20170336420A1 (en) * 2014-11-04 2017-11-23 Rappaport Family Institute For Research In The Medical Sciences Methods and kits for treating cardiovascular diseases

Also Published As

Publication number Publication date
TW201929894A (zh) 2019-08-01
WO2019092584A1 (fr) 2019-05-16
CN111601614A (zh) 2020-08-28
EP3706781A4 (fr) 2021-07-21
AU2018362603A1 (en) 2020-06-18
SG11202003835PA (en) 2020-05-28
CA3082070A1 (fr) 2019-05-16
EP3706781A1 (fr) 2020-09-16
US20200261549A1 (en) 2020-08-20
IL274360A (en) 2020-06-30
KR20200085292A (ko) 2020-07-14
JP2021501793A (ja) 2021-01-21

Similar Documents

Publication Publication Date Title
EP3490582A4 (fr) Méthodes et compositions de traitement de maladie.
EP3481402A4 (fr) Composés, compositions et méthodes de traitement de maladie
EP3607072A4 (fr) Compositions et méthodes de traitement de la phénylcétonurie
EP3291815A4 (fr) Méthodes de traitement d'une maladie neurodégénérative
EP3294345A4 (fr) Formulations de tpp1 et méthodes de traitement de la maladie cln2
EP3706737A4 (fr) Inhibiteurs de ash1l et méthodes de traitement comprenant ces derniers
EP2981551A4 (fr) Méthodes et compositions pour le traitement de la maladie de pompe
EP2854850A4 (fr) Méthodes de traitement du syndrome gastro-intestinal et de la maladie du greffon contre l'hôte
EP3875139C0 (fr) Traitement des maladies veineuses
EP3294761A4 (fr) Compositions et méthodes de traitement et de prévention de l'infection pare. coli
EP3496844C0 (fr) Calcification vasculaire et prévention et traitement de maladies cardiovasculaires/associées
EP2854839A4 (fr) Méthodes de traitement de la maladie c liaque
MA45149A (fr) Méthodes de traitement de la maladie d'alzheimer
IL269083A (en) Methods for preventing and treating heart disease
EP3658142A4 (fr) Compositions et méthodes de traitement de la galactosémie
EP3599983A4 (fr) Endoscopes et méthodes de traitement
EP3546449A4 (fr) Dérivé de pipéridine -2,6-dicétone et traitement de la maladie de crohn
EP3518898A4 (fr) Prévention et traitement de néphropathie diabétique
MA50914A (fr) Vecteurs viraux comprenant des séquences codantes de rdh12 et méthodes de traitement de dystrophies rétiniennes
EP3322406A4 (fr) Méthodes et compositions transpapillaires pour le traitement des affections mammaires
IL256329B (en) Carbazole derivatives for the treatment of fibrotic diseases, symptoms and conditions related to them
MA50582A (fr) Méthodes de traitement et de protection contre une maladie cardiaque, une maladie cardiovasculaire et des états et des symptômes associés
MA43755A (fr) Méthodes de traitement ou de prévention d'une maladie du greffon contre l'hôte
EA201692202A1 (ru) Способы лечения сердечно-сосудистых заболеваний
EP3694517A4 (fr) Compositions et méthodes de traitement de la fibrose